

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

NEPTUNE GENERICS, LLC,  
APOTEX INC., APOTEX CORP., TEVA PHARMACEUTICALS,  
FRESENIUS KABI USA, LLC, and  
WOCKHARDT BIO AG,

PETITIONERS,

V.

ELI LILLY & COMPANY,

PATENT OWNER.

---

Case IPR2016-00240<sup>1</sup>  
Patent 7,772,209

---

**PETITIONER'S CURRENT EXHIBIT LIST AS OF APRIL 7, 2017  
PURSUANT TO 37 C.F.R. § 42.63(e)**

---

<sup>1</sup> Cases IPR2016-01191, IPR2016-01337 and IPR2016-01343 have been joined with the instant proceeding.

**PETITIONER'S CURRENT EXHIBIT LIST**

(Updated April 7, 2017)

<b>Exhibit No.</b>	<b>Description</b>
<b>Exhibit 1001</b>	U.S. Patent No. 7,772,209 to Clet Niyikiza, filed on July 11, 2007, and issued on Aug. 10, 2010 (“the ’209 patent”)
<b>Exhibit 1002</b>	U.S. Patent No. 7,772,209 Prosecution History (“’209 prosecution history”)
<b>Exhibit 1003</b>	U.S. Patent No. 5,344,932 to Edward C Taylor, issued on Sep. 6, 1994 (“ <i>Taylor</i> ”)
<b>Exhibit 1004</b>	Claim Chart for Niyikiza ’209 Petition (Attachment 2 to Bleyer Declaration)
<b>Exhibit 1005</b>	Worzalla et al., “Role of Folic Acid in Modulating the Toxicity and Efficacy of the Multitargeted Antifolate, LY231514.” <i>Anticancer Research</i> 18:3235-3240 (1998) (“ <i>Worzalla</i> ”)
<b>Exhibit 1006</b>	U.S. Patent No. 4,140,707 to Cleare et al., issued on Feb. 20, 1979 (“ <i>Cleare</i> ”)
<b>Exhibit 1007</b>	Tsao CS, “Influence of Cobalamin on the Survival of Mice Bearing Ascites Tumor.” <i>Pathobiology</i> 1993;61:104-108 (“ <i>Tsao</i> ”)
<b>Exhibit 1008</b>	Niyikiza et al., “MTA (LY231514): Relationship of vitamin metabolite profile, drug exposure, and other patient characteristics to toxicity.” <i>Annals of Oncology</i> , Vol. 9, Suppl. 4, 1998, Abstract 609P, pg. 126 (“ <i>Niyikiza</i> ”)
<b>Exhibit 1009</b>	Curriculum Vitae of W. Archie Bleyer, M.D., FRCP[Glasg] (Attachment 1 to Bleyer Declaration)
<b>Exhibit 1010</b>	European Patent Application No. 0,595,005 A1 (“ <i>EP 005</i> ”)
<b>Exhibit 1011</b>	Rusthoven et al., “Multitargeted Antifolate LY231514 as First-Line Chemotherapy for Patients with Advanced Non-Small-Cell Lung Cancer: A Phase II Study.” <i>Journal of Clinical Oncology</i> , Vol. 17, No. 4, (April 1999), pp. 1194-1199 (“ <i>Rusthoven</i> ”)
<b>Exhibit 1012</b>	Refsum H & Ueland PM, “Clinical significance of pharmacological modulation of homocysteine metabolism.” <i>Trends in Pharmacol. Sci.</i> , Vol. 11, No. 10, 1990, pp. 411-416 (“ <i>Refsum</i> ”)

Exhibit No.	Description
<b>Exhibit 1013</b>	Calvert AH & Walling JM, "Clinical studies with MTA." British Journal of Cancer (1998) 78 (Suppl. 3), 35-40 (" <i>Calvert 1998</i> ")
<b>Exhibit 1014</b>	Calvert H, "An Overview of Folate Metabolism: Features Relevant to the Action and Toxicities of Antifolate Anticancer Agents," Seminars in Oncology, Vol. 26, No. 2, Suppl 6 (April), 1999, pp.3-10 (" <i>Calvert 1999</i> ")
<b>Exhibit 1015</b>	O'Dwyer et al., "Overview of Phase II Trials of MTA in Solid Tumors." Seminars in Oncology, Vol. 26, No. 2, Suppl 6 (April), 1999, pp. 99-104 (" <i>O'Dwyer</i> ")
<b>Exhibit 1016</b>	Zervos et al., "Functional folate status as a prognostic indicator of toxicity in clinical trials of the multitargeted antifolate LY231514." Proceedings of ASCO, Vol. 16, 1997, pg. 256a (" <i>Zervos</i> ")
<b>Exhibit 1017</b>	Allen et al., "Diagnosis of Cobalamin Deficiency I: Usefulness of Serum Methylmalonic Acid and Total Homocysteine Concentrations." American Journal of Hematology, 34, 1990, 90-98 (" <i>Allen</i> ")
<b>Exhibit 1018</b>	Savage et al., "Sensitivity of Serum Methylmalonic Acid and Total Homocysteine Determinations for Diagnosing Cobalamin and Folate Deficiencies. The American Journal of Medicine, 96: 1994, 239-246 (" <i>Savage</i> ")
<b>Exhibit 1019</b>	Brönstrup et al., "Effects of folic acid and combinations of folic acid and vitamin B-12 on plasma homocysteine concentrations in healthy, young women." Am. J. Clin. Nutr. Vol. 68, 1998, 1104-10 (" <i>Bronstrup</i> ")
<b>Exhibit 1020</b>	Carrasco et al., "Acute megaloblastic anemia: homocysteine levels are useful for diagnosis and follow-up." Haematologica, Vol. 84(8), August 1999, 767-768 (" <i>Carrasco</i> ")
<b>Exhibit 1021</b>	Thödttmann et al., "Phase I study of different sequences of MTA (LY231514) in combination with cisplatin in patients with solid tumours." Annals of Oncology, Vol. 9, Suppl. 4, 1998, Abstract 618P, pg. 129 (" <i>Thodtman</i> ")

Exhibit No.	Description
<b>Exhibit 1022</b>	Hammond et al., “A Phase I and pharmacokinetic (PK) study of the multitargeted antifolate (MTA, LY231514) with folic acid (FA).” <i>Annals of Oncology</i> , Vol. 9, Suppl. 4, 1998, Abstract 620P, pg. 129 (“ <i>Hammond</i> ”)
<b>Exhibit 1023</b>	Morgan et al., “The Effect of Folic Acid Supplementation on the Toxicity of Low-Dose Methotrexate in Patients with Rheumatoid Arthritis.” <i>Arthritis and Rheumatism</i> , Vol. 33, No. 1, January 1990, pp. 9-18 (“ <i>Morgan</i> ”) (Ex. 1023)
<b>Exhibit 1024</b>	Declaration of W. Archie Bleyer, M.D., FRCP[Glasg]
<b>Exhibit 1025</b>	<i>Eli Lilly and Company v. Teva Parental Medicines, Inc., et al.</i> , INSD-1:10-cv-01376 Markman Order (June 20, 2012) (“ <i>Teva</i> ”)
<b>Exhibit 1026</b>	<i>Eli Lilly and Company v. Teva Parental Medicines, Inc., et al.</i> , INSD-1:10-cv-01376 Joint Claim Construction Brief (April 19, 2012) (“ <i>Teva Claim Construction</i> ”)
<b>Exhibit 1027</b>	<i>Eli Lilly and Company v. Teva Parental Medicines, Inc., et al.</i> , INSD-1:10-cv-01376 Decision (March 31, 2014) (“ <i>Teva Decision</i> ”)
<b>Exhibit 1028</b>	Curriculum Vitae of Scott Bennett, Ph.D.
<b>Exhibit 1029</b>	Declaration of Scott Bennett, Ph.D.
<b>Exhibit 1030</b>	Online copy of Rusthoven from the Web site of the Journal of Clinical Oncology
<b>Exhibit 1031</b>	University of Illinois at Urbana-Champaign Library directory entry for the Journal of Clinical Oncology
<b>Exhibit 1032</b>	Statewide Illinois Library Catalog record for the Journal of Clinical Oncology
<b>Exhibit 1033</b>	Copy of Rusthoven from the University of Illinois at Chicago Library
<b>Exhibit 1034</b>	Web of Science entry for Rusthoven
<b>Exhibit 1035</b>	Online copy of <i>Carrasco</i> from the Highwire Press
<b>Exhibit 1036</b>	University of Illinois at Urbana-Champaign Library directory entry for <i>Haematologica</i>
<b>Exhibit 1037</b>	Statewide Illinois Library Catalog record for <i>Haematologica</i>

Exhibit No.	Description
<b>Exhibit 1038</b>	Copy of <i>Carrasco</i> from the University of Michigan Taubman Medical Library
<b>Exhibit 1039</b>	Web of Science entry for <i>Carrasco</i>
<b>Exhibit 1040</b>	Declaration of Mieke K. Malmberg
<b>Exhibit 1041</b>	Declaration of Paul J. Skiermont
<b>Exhibit 1042</b>	Transcript of October 31, 2016 Telephone Hearing
<b>Exhibit 1043</b>	Tashjian, AH J, and BA Chabner. "Commentary on Clinical Safety of Recombinant Human Parathyroid Hormone 1-34 in the Treatment of Osteoporosis in Men and Postmenopausal Women." <i>Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research</i> . 17.7 (2002): 1151-61. Print. (Previously introduced as Ex. 1043 in Dr. Chabner's deposition.)
<b>Exhibit 1044</b>	Tefferi, A, H Kantarjian, S V. Rajkumar, L H. Baker, J L. Abkowitz, J W. Adamson, R H. Advani, J Allison, K H. Antman, and R C. Bast. "In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs." <i>Mayo Clinic Proceedings</i> . 90.8 (2015): 996-1000. Print. (Previously introduced as Ex. 1044 in Dr. Chabner's deposition.)
<b>Exhibit 1045</b>	Singh, H, D L. Longo, and B A. Chabner. "Improving Prospects for Targeting Ras." <i>Journal of Clinical Oncology</i> . 33.31 (2015): 3650-3659. Print. (Previously introduced as Ex. 1045 in Dr. Chabner's deposition.)
<b>Exhibit 1046</b>	Information for Contributors, <a href="http://theoncologist.alphamedpress.org/site/misc/InfoForContributors.xhtml#_Toc374525716">theoncologist.alphamedpress.org/site/misc/InfoForContributors.xhtml#_Toc374525716</a> (viewed on 11/15/2016). (Previously introduced as Ex. 1046 in Dr. Chabner's deposition.)
<b>Exhibit 1047</b>	Hanuske, AR, V Chen, P Paoletti, and C Niyikiza. "Pemetrexed Disodium: a Novel Antifolate Clinically Active against Multiple Solid Tumors." <i>The Oncologist</i> . 6.4 (2001): 363-73. Print. (Previously introduced as Ex. 1047 in Dr. Chabner's deposition.)
<b>Exhibit 1048</b>	Chabner BA., hand drawn sketch. (Previously introduced as Ex. 1048 in Dr. Chabner's deposition.)

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.